7-Ethyl-10-hydroxycamptothecin (SN-38)

7-Ethyl-10-hydroxycamptothecin (SN-38)
Product Description

Avra Laboratories is first Company in the world to develop a synthetic route for manufacturing of camptothecin derivatives. Avra manufacturing 7-Ethyl-10-hydroxycamptothecin (SN-38)  in dedicated oncology facility which is approved by USFDA. we support  USDMF  and regulatory  filing .  offer 1 kg to 50 kgs level.

Advantages of SN-38:
Our product is made by total synthesis as against other products available in the market.
Consistent quality in terms of purity and impurity profile.
Better yield of Irinotecan per gm of SN-38.
We will provide support both in terms of technical support and regulatory requirements.

Read more Show less

Avra Laboratories Pvt. Ltd.

  • IN
  • 2015
    On CPHI since
View company profile
Specifications
  • Supplied from
    India
  • Measured In
    kilogram
More specifications Fewer specifications

Avra Laboratories Pvt. Ltd.

  • IN
  • 2015
    On CPHI since
View company profile

More Products from Avra Laboratories Pvt. Ltd. (2)

  • 10-hydroxycamptothecin

    Product 10-hydroxycamptothecin

    Avra Laboratories is first Company in the world to develop a synthetic route 10-hydroxycamptothecin. manufacturing in USFDA approved facility and support  USDMF for regulatory fillings (key intermediate of Topotecan).

  • Irinotecan Hcl

    Product Irinotecan Hcl

    Avra developed an optimal process for the total synthesis of SN-38 and its conversion to Irinotecan Hcl USP and give more purity (Assay) NLT 99%. manufacturing in USFDA approved facility and support regulatory requirements.
    USDMF and EDMF available